MacroGenics Reports Positive Interim Phase 1 Results for MGC026
MacroGenics announced positive interim results from its Phase 1 study of MGC026, a B7-H…
Story updates
01:17:31 PM UTC
SquawkNews
MacroGenics reported positive interim Phase 1 results for B7-H3 ADC MGC026, including a 27% response rate in heavily pretreated SCCHN, and plans to start a front-line pembrolizumab combination cohort in PD-L1+ SCCHN in early 2027.Material DetailsContext by AI AnalystEarly clinical signal for MGC026…